Message from NPC
Join NPC in a Conversation About Health Care Spending With the New Going Below the Surface E-newsletter
One of the most pressing issues facing our nation is how to optimize health care spending in a way that sustains next-generation innovation while continuing to improve overall patient well-being and health system efficiencies. The National Pharmaceutical Council (NPC) is pleased to announce the launch of a new e-newsletter, Going Below the Surface, that is solely focused on this vital issue.
This monthly e-newsletter will take a critical look at our health care system and advance important conversations around how we spend our nation’s health care dollars. With partners across the health care industry, NPC sponsors and promotes research that gets to the root of our nation’s spending on health care, as well as what we are getting in return.
Subscribe today to begin receiving timely updates about relevant peer-reviewed journal articles, commentary on emerging trends and themes that relate to the broader issue of health care spending in the United States. Watch for the first issue coming this Wednesday.
NPC Now: A Look At Our Latest Work
When and How Are Individual Patient Differences Studied, and What Does it Mean for Personalized Medicine?
Scientists recognize that individual patients may react differently to a particular health treatment, even if it works well for the average patient population with the same condition. Research published in BMJ Open indicates that these individual differences are rarely studied, although individual responses to treatments are common and often substantial. The study strongly indicates that for certain conditions, the “average” patient is just a myth; a treatment that works well in some patients may not work well for other individuals.
How Do Medical Technology Innovations Impact Patient Outcomes?
A new survey from RTI Health Solutions and NPC tackles the concept of innovation by asking physicians—a group well-versed in what medical advances move the needle for patients—about what improvements have changed treatment practices in their areas of expertise. According to the research, published in the Journal of Managed Care & Specialty Pharmacy, new biopharmaceuticals have driven innovation over the past 25 years, re-shaping our treatment of diseases in profound ways. The findings suggest we may, in fact, be under-investing in the most valuable facet of health technology.
Research and Info You Need to Know
FDA Clarifies What Information Can Be Exchanged With Health Decision-makers
With the release of two guidance documents last week, the U.S. Food and Drug Administration took significant steps to modernize how health care information is communicated. One guidance makes important improvements to expand the exchange of clinical and economic information for biopharmaceuticals, medical devices, and unapproved products and unapproved uses of existing products among biopharmaceutical manufacturers, payers and population-health decision makers. A second guidance outlines the communication of information consistent with, but not contained in, a product label to providers and the public.
ICYMI: Articles of Note
- Dunn A, et al. High Spending Growth Rates For Key Diseases In 2000–14 Were Driven By Technology And Demographic Factors. Health Affairs. June 2018.
- Robinson JC, Howell S, Pearson SD. Value-Based Pricing and Patient Access for Specialty Drugs. JAMA. June 5, 2018.
- Kaltenboeck A, Bach PB. Value-Based Pricing for Drugs: Theme and Variations. JAMA. June 5, 2018.
Events and Education
NPC Webinar: Barriers to Paying for Value
Join NPC for a webinar, "Barriers to Paying for Value," highlighting its recently published paper examining how regulatory barriers limit value-based contracting. The webinar will discuss barriers to financing curative therapies, a comprehensive solution for Medicaid’s Best Price policy and take a deeper dive into the anti-kickback statute. Register now to join us on Tuesday, June 26, from 12 p.m.–1 p.m. Eastern Time.
Webinar: Current IRS Policy on High-Deductible Health Plans: Impacting Americans with Chronic Conditions
Join the National Health Council for a webinar, co-sponsored by NPC, that will focus on a recent NPC-funded study examining how current IRS policy on high-deductible health plans and health savings accounts impacts Americans living with chronic conditions. Dr. A. Mark Fendrick, director of the University of Michigan's Center for Value-Based Insurance Design, will present findings from the study and participate in an audience question-and-answer session. Sign up now to attend this webinar on Tuesday, June 26, from 3:30 p.m.-4:30 p.m. Eastern Time.
NPC @ MedCity CONVERGE
Join NPC and health care stakeholders at MedCity CONVERGE in Philadelphia, Pennsylvania, on July 11-12 for a two-day summit on oncology innovation. NPC Chief Science Officer and Executive Vice President Robert W. Dubois, MD, PhD, will address “Promising Drugs, Pricing and Access” in a panel discussion on Thursday, July 12, from 10:30 a.m.-11:45 a.m. Learn more and register now.
NPC @ National Academies of Sciences, Engineering and Medicine’s Real-world Evidence Workshop
The National Academies of Sciences, Engineering, and Medicine is convening the third workshop in a three-part series, sponsored by the U.S. Food and Drug Administration, examining and suggesting approaches for operationalizing the collection and use of real-world evidence (RWE) on July 17-18 in Washington, D.C. NPC Vice President of Comparative Effectiveness Research Jennifer Graff, PharmD, will moderate a session on “Treatment Quality and Participant Safety in Pragmatic Trials” on Tuesday, July 17, at 3:05 p.m. For more information and registration details, visit NPC’s website.